We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report.
- Authors
Osugi, Jun; Owada, Yuki; Yamaura, Takumi; Muto, Satoshi; Okabe, Naoyuki; Matsumura, Yuki; Higuchi, Mitsunori; Suzuki, Hiroyuki; Gotoh, Mitsukazu
- Abstract
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.
- Subjects
CRIZOTINIB; NEUTROPENIA; ANAPLASTIC lymphoma kinase
- Publication
Case Reports in Oncology, 2016, Vol 9, Issue 1, p51
- ISSN
1662-6575
- Publication type
Case Study
- DOI
10.1159/000443662